Although these findings require further validation in human models, an interesting analysis of data from the Cancer Genome Atlas (TCGA) has shown low expression of PHD3 in obese patients with colorectal cancer (CRC) and, notably, in other human cancers, suggesting the intriguing possibility that blocking metabolic rewiring in tumor cells may improve antitumor immunity. The gene discussed is EGLN3; the disease is neoplasm.